Michel KLEIN is an internationally recognized expert in Vaccinology. He graduated from the Faculty of Medicine and the Institut Pasteur of Paris. He has been a Professor of Immunology at the University of Toronto and has 25 years of experience invaccine research and development. He held the position of Vice President Research at Pasteur Mérieux Connaught and that of Corporate Vice President,Science and Technology, of the Aventis-Pasteur Group (now Sanofi Pasteur) until 2002 when he retired. He then held the position of Chief Executive Officer of the Canadian Network for Vaccines and Immunotherapeutics until 2006. He servedas a member of the EDCTP Partnership Board of the European Union until 2007, Hewas Visiting Professor at the National Health Research Institutes of Taiwan and is today Chief Operating Officer at BravoVax (Wuhan).
He has developed the five-component acellular pertussis vaccine currently on the world market, as well as PIV-3, RSV, influenza virus HIV, and cancer vaccines during his tenureat Sanofi Pasteur and actively contributed to the development of the TaiwaneseH5N1 and EV71 vaccines.
He is the author of more than 200 scientific publications and patents in the fields of vaccinology, immunology,infectious diseases and biotechnology. He is a member of several Boards of Directors and Scientific Advisory Boards. He is a knight in the French order ofthe Légion d’Honneur.
客服热线：400 610 1188